PD-1在4NQO诱导的小鼠口腔黏膜鳞癌中表达变化

›› 2020, Vol. 40 ›› Issue (7): 593-596.

PD-1在4NQO诱导的小鼠口腔黏膜鳞癌中表达变化

张柏林¹,李岩²,朱雪琴¹,蒋英英³,陈万涛⁴

1. 上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科
2. 齐齐哈尔医学院口腔医学院
3. 潍坊医学院
4. 上海交通大学医学院附属第九人民医院

收稿日期:2020-01-14 修回日期:2020-03-10 出版日期:2020-07-28 发布日期:2020-07-20
通讯作者: 陈万涛 E-mail:chenwantao2002@hotmail.com
基金资助:
基于MAL基因敲除和4NQO暴露建立口腔鳞癌动物模型及分子生物学性状分析;上海市口腔颌面部肿瘤组织样本及生物信息数据库专业技术服务平台

Alteration of PD-1 expression in mice oral squamous cell carcinoma induced by 4-nitroquinoline-1-oxide

Received:2020-01-14 Revised:2020-03-10 Online:2020-07-28 Published:2020-07-20

摘要/Abstract

摘要： 研究程序性死亡蛋白1 ( programmed cell death1，PD-1)在小鼠口腔黏膜鳞癌微环境中的变化和可能作用。方法　利用化学致癌剂4-硝基喹啉-1-氧化物（4-nitroquinoline-1-oxide，4NQO）饮水诱导建立C57小鼠口腔黏膜鳞癌动物模型。对小鼠模型口腔黏膜肿瘤病变部位进行组织病理学检测和分析；通过Real-time PCR和流式细胞术检测免疫检查点PD-1基因和蛋白的表达水平。结果　在暴露4NQO 28周后，成功诱导小鼠发生口腔黏膜鳞癌。组织病理学结果显示，小鼠发生的肿瘤为口腔黏膜鳞癌。Real-time PCR和流式细胞术检测结果表明，小鼠舌部黏膜肿瘤组织和脾脏中的CD4+ T细胞，PD-1基因和蛋白表达都明显上调。结论　免疫检查点PD-1在小鼠口腔黏膜鳞癌发生中出现明显升高，PD-1与口腔黏膜鳞癌的发展可能相关。

关键词: 小鼠口腔黏膜, 4-硝基喹啉-1-氧化物, 口腔鳞状细胞癌, PD-1

Abstract: Objective　 To identify the changes and potential roles of immune checkpoint PD-1 in oral squamous cell carcinoma (OSCC) microenvironment. Methods　 The oral squamous cell carcinoma model of C57 mice was induced and established by potable water containing 4-nitroquinoline-1-oxide (4NQO). Lesion location of the oral squamous cell carcinoma of the mice model was detected and analyzed by histopathology. Real-time PCR and flow cytometry were used to detect the expression level of PD-1 gene and protein. Results　 OSCC model was successfully induced by exposing to 4NQO after 28 weeks. Histopathological evaluation showed that oral mucosal squamous cell carcinoma occurred in mice. Real-time PCR and flow cytometry showed that PD-1 gene and protein expression in CD4+ T cell was significantly up-regulated in tongue mucosal tumor tissues and spleen. Conclusion　 PD-1 shows significant up-regulation in mice OSCC and is possibly related to the development of OSCC.

Key words: mice oral mucosa, 4-nitroquinoline-1-oxide, oral squamous cell carcinoma, PD-1

中图分类号:

R839.85

张柏林李岩朱雪琴蒋英英陈万涛. PD-1在4NQO诱导的小鼠口腔黏膜鳞癌中表达变化[J]. 口腔医学, 2020, 40(7): 593-596.

参考文献 21

[1]	CHI A C, DAY T A, NEVILLE B W. Oral cavity and oropharyngeal squamous cell carcinoma--an update[J]. CA Cancer J Clin, 2015, 65(5):401-21.
[2]	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30.
[3]	OLIVEIRA-COSTA J P, DE CARVALHO A F, DA SILVEIRA DA G G, et al. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells[J]. Oncotarget, 2015, 6(25):20902-20.
[4]	WEI S C, ANANG N A S, SHARMA R, et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies[J]. Proc Natl Acad Sci U S A, 2019.
[5]	CHEN L, HAN X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future[J]. J Clin Invest, 2015, 125(9):3384-91.
[6]	TOPALIAN S L, HODI F S, BRAHMER J R, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26):2443-54.
[7]	SEIWERT T Y, BURTNESS B, MEHRA R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016, 17(7):956-965.
[8]	SCULLY C, BAGAN J V. Recent advances in oral oncology 2008; squamous cell carcinoma imaging, treatment, prognostication and treatment outcomes[J]. Oral Oncol, 2009, 45(6):e25-30.
[9]	GILDENER-LEAPMAN N, FERRIS R L, BAUMAN J E. Promising systemic immunotherapies in head and neck squamous cell carcinoma[J]. Oral Oncol, 2013, 49(12):1089-96.
[10]	TAKAHASHI H, YANAMOTO S, YAMADA S, et al. Effects of postoperative chemotherapy and radiotherapy on patients with squamous cell carcinoma of the oral cavity and multiple regional lymph node metastases[J]. Int J Oral Maxillofac Surg, 2014, 43(6):680-5.
[11]	HUGHES P E, CAENEPEEL S, WU L C. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer[J]. Trends Immunol, 2016, 37(7):462-476.
[12]	ROTTE A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer[J]. J Exp Clin Cancer Res, 2019, 38(1):255.
[13]	LEE H T, LEE S H, HEO Y S. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology[J]. Molecules, 2019, 24(6).
[14]	FORSCHNER A, BATTKE F, HADASCHIK D, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study[J]. J Immunother Cancer, 2019, 7(1):180.
[15]	MIRANDA S R, NOGUTI J, CARVALHO J G, et al. Oxidative DNA damage is a preliminary step during rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide[J]. J Mol Histol, 2011, 42(2):181-6.
[16]	KANOJIA D, VAIDYA M M. 4-nitroquinoline-1-oxide induced experimental oral carcinogenesis[J]. Oral Oncol, 2006, 42(7):655-67.
[17]	吴祥冰. TGM3和MAL基因在口腔鳞癌发生发展中作用[D]. 上海交通大学, 2014.
[18]	FERRIS R L, BLUMENSCHEIN G, JR., FAYETTE J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck[J]. N Engl J Med, 2016, 375(19):1856-1867.
[19]	MATTOX A K, LEE J, WESTRA W H, et al. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4(+) TILs in the Presence of PD-L1(+) TAMs[J]. Cancer Res, 2017, 77(22):6365-6374.
[20]	LUI V W, HEDBERG M L, LI H, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers[J]. Cancer Discov, 2013, 3(7):761-9.
[21]	IGLESIAS-BARTOLOME R, MARTIN D, GUTKIND J S. Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets[J]. Cancer Discov, 2013, 3(7):722-5.